Please assess the completion status of the following clinical trial:

Trial Title: Colorectal Cancer (CRC) Cetuximab Elderly Frail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed metastatic colorectal cancer~* Measurable disease according to RECIST V1.1~* Histological local review and analysis of KRAS~* Age ≥ 80 or ≥ 70 in combination with functional restrictions defined as limitation in at least 2 of 8 IADL~* WHO performance status 0, 1 or 2~* Adequate bone marrow reserves, hepatic function \& renal function~* Normal 12 lead ECG without clinically significant abnormalities~* Written informed consent before randomization according to ICH/EU GCP, and local, national and international regulations~Exclusion Criteria:~* Prior systemic chemotherapy for metastatic disease~* Previous exposure to EGFR or VEGF/VEGFR targeted therapy~* Patients may have received chemotherapy in the adjuvant or neoadjuvant setting (CRC). The treatment-free interval should be 6 months or more from the end of (neo-)adjuvant therapy~* Previous radiotherapy, either in the adjuvant setting or for the treatment of bone metastases, is allowed provided that the measurable lesions are outside the radiation fields~* Persistence of clinically relevant treatment-related toxicities from previous chemotherapy and/or radiotherapy (adjuvant or neo-adjuvant setting)~* Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of treatment or concomitantly with this trial~* Known alcohol or drug abuse~* Clinically significant cardiovascular disease~* Evidence of uncontrolled medical comorbidities despite adequate treatment~* Patients who have suffered a cerebrovascular accident or transient ischemic attack within the past 12 months~* History, within the past 5 years, of malignancies other than CRC~* Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and followup schedule

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5-fluorouracil/leucovorin plus cetuximab (Type: EXPERIMENTAL): None
- 5-fluorouracil/leucovorin alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).